arrow
E

Erik P. Sulman

Duke University School of Medicine
H指数:75
被引数:3.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Spatiotemporal Evolution of Radiation Resistance in Glioblastoma

胶质母细胞瘤中辐射抵抗的空间-时间演变

2026-09-150
PRE
Persistent chromatin alterations and gene expression reprogramming follow widespread DNA damage in glioblastoma

广泛DNA损伤后的胶质母细胞瘤中持续的染色质改变和基因表达重编程

2026-08-290
OA
NOTQ-04 NEUROCOGNITIVE OUTCOMES IN PATIENTS WITH BRAIN METASTASES: A SYSTEMATIC REVIEW OF PAST FINDINGS AND FUTURE DIRECTIONS

NOTQ-04 脑转移患者神经认知结局:既往发现和未来方向的系统综述

2026-08-070
OA
Neurocognitive outcomes in patients with brain metastases: a systematic review

脑转移瘤患者的神经认知结局:一项系统综述

2025-11-240
PRE
IMG-72. [68Ga]Ga-DOTA-TATE PET as imaging biomarker for response assessment and monitoring in patients receiving [177Lu]Lu-DOTA-TATE for advanced intracranial meningioma

IMG-72. [68Ga]Ga-DOTA-TATE PET作为评估和监测接受[177Lu]Lu-DOTA-TATE治疗的颅内高级别脑膜瘤患者的影像学生物标志物

2025-11-110
OA
TIP-15. Trial in progress: phase IB study of concurrent Azeliragon, a RAGE inhibitor, with craniospinal irradiation in patients with leptomeningeal metastases

TIP-15. 试验进行中:一项关于在软脑膜转移患者中与全脑脊髓放疗同步使用Azeliragon(一种RAGE抑制剂)的IB期研究

2025-11-110
OA
Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples

基因组与表观基因组特征能够区分临床级样本中侵袭性的嗜酸性肾细胞癌与惰性的肾源性肿瘤。

2025-11-040
PRE
Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

GBM AGILE更新:一项全球性、II/III期自适应平台试验,旨在评估新诊断和复发性胶质母细胞瘤中的多种治疗方案

2025-11-010
OAAI
RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF THE RADIOPHARMACEUTICAL [177LU]LU-DOTA-TATE IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA

单臂、开放标签、多中心II期研究中,放射性药物[177Lu]Lu-DOTATATE在成人晚期颅内脑膜瘤患者中的研究结果

2025-11-010
OAAI
MOMENTUM-1: a multicenter, randomized, open-label, phase 2 study of [177Lu]Lu-DOTA-TATE in adults with progressive grade 1-3 meningioma (RTOG 3523)

MOMENTUM-1:一项多中心、随机、开放标签的II期研究,评估[177Lu]Lu-DOTA-TATE在进展性1-3级脑膜瘤成人患者中的疗效(RTOG 3523)。

2025-11-010
OAAI
A novel, pooled, high-throughput screening of a CNS penetrant compound library identifies potential biomarker-driven therapeutics for glioblastoma

一种新颖的、集成的、高通量筛选方法对一种能穿透CNS的化合物库进行筛选,以识别潜在生物标志物驱动的胶质母细胞瘤治疗方法

2025-11-010
OAAI
Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825
2024-11-160
PRE
EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

PAXALISIB在新诊断和复发胶质母细胞瘤的GBM敏捷3期注册平台试验中的评估

2024-11-110
PRE